Amyloid β accumulation assessed with 11C-pittsburgh compound B PET and postmortem neuropathology

Current Alzheimer Research

Volumn 12, Issue 3, 2015, Pages 278-286

  Hatsuta, Hiroyuki ^a,b   Takao, Masaki ^a,b   Ishii, Kenji ^a,b   Ishiwata, Kiichi ^a   Saito, Yuko ^c   Kanemaru, Kazutomi ^b   Arai, Tomio ^b   Suhara, Tetsuya ^d   Shimada, Hitoshi ^d   Shinotoh, Hitoshi ^d,e   Tamaoka, Akira ^f   Murayama, Shigeo ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c National Center Hospital of Neurology and Psychiatry Kodaira   (Japan)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^e Neurology Chiba   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

11C Pittsburgh compound B (PiB); Alzheimer s disease; Amyloid beta protein; Autopsy; Positron emission tomography (PET); Senile plaques

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[11-28]; MONOCLONAL ANTIBODY; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE; TRITIUM;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN REGION; DISEASE MARKER; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SENILE PLAQUE; VERY ELDERLY; BRAIN MAPPING; DEMENTIA; METABOLISM; PATHOLOGY; POSTMORTEM CHANGE; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; SCINTISCANNING; STATISTICS;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN MAPPING; CEREBRAL CORTEX; DEMENTIA; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; POSTMORTEM CHANGES; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; THIAZOLES; TRITIUM;

EID: 84928995389     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150302155930     Document Type: Article

References (34)

1. Association AP. Diagnostic and statistical manual of mental disorders (IV-TR). 4th edn-text revised. 2000; Washington DC.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8): 734-46 (2007).
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3): 306-19 (2004).
4. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al.Imaging beta-amyloid burden in aging and dementia. Neurology 68(20): 1718-25 (2007).
5. Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131(Pt 3): 665-80 (2008).
6. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al.Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65(5): 557-68 (2009).
7. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al.Amyloid, hypometabolism, and cognition in Alzheimer disease: an 11CPIB and 18FFDG PET study. Neurology 68(7): 501-8 (2007).
8. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al.Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31(8):1275-83 (2010).
9. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al.PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29(10): 1456-65 (2008).
10. Koivunen J, Pirttila T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, et al.PET amyloid ligand [11C] PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 26(4): 378-83 (2008).
11. Reiman E, Jagust W. Brain imaging in the study of Alzheimer's disease. Neuroimage 61(2): 505-16 (2012).
12. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al.Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 65(10): 1304-9 (2008).
13. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al.Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131(Pt 6): 1630-45 (2008).
14. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al.Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64(3): 431-4 (2007).
15. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al.Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 66(12): 1557-62 (2009).
16. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74(1): 77-84 (2010).
17. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 52(11): 1733-40 (2011).
18. Sojkova J, Resnick SM. In vivo human amyloid imaging. Curr Alzheimer Res 8(4): 366-72 (2011).
19. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al.Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 48(4): 547-52 (2007).
20. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, et al.Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67(10): 945-53 (2008).
21. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, et al.Incidence and extent of Lewy body-related alphasynucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67(11): 1072-83 (2008).
22. Adachi T, Saito Y, Hatsuta H, Funabe S, Tokumaru A, Ishii K, et al.Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69(7): 737-44 (2010).
23. Funabe S, Takao M, Saito Y, Hatsuta H, Sugiyama M, Ito S, et al.Neuropathologic analysis of Lewy-related alpha-synucleinopathy in olfactory mucosa. Neuropathology 33(1): 47-58 (2012).
24. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al.The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4): 479-86 (1991).
25. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al.National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123(1): 1-11 (2012).
26. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al.National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8(1):1-13 (2012).
27. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4): 389-404 (2006).
28. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82(4): 239-59 (1991).
29. Hatsuta H, Takao M. Amyloid beta protein. Pathol Clin Med 29: 84-91 (2011).
30. Tomonaga M. Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 29(4): 151-7 (1981).
31. Lockhart A, Ye L, Judd D, Merritt A, Lowe P, Morgenstern J, et al.Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280(9): 7677-84 (2004).
32. Ye L, Morgenstern J, Gee A, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280(25): 23599-604 (2005).
33. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, et al.Assessment of amyloid in a fronatl cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 65(10): 1304-9 (2008).
34. Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, et al.Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 110(47): E4502-9 (2013).